DETERMINATION OF PLASMA-CONCENTRATIONS OF AMIKACIN IN PATIENTS OF AN INTENSIVE-CARE UNIT

被引：3

作者：

PIMENTEL, FL ^{[1
]}

ABELHA, F ^{[1
]}

TRIGO, MA ^{[1
]}

SA, LV ^{[1
]}

MENEZES, MR ^{[1
]}

机构：

[1] HOSP SAO JOAO,SERV MED 4,OPORTO,PORTUGAL

来源：

JOURNAL OF CHEMOTHERAPY | 1995年 / 7卷 / 01期

关键词：

AMIKACIN; PHARMACOKINETICS; BLOOD DETERMINATION; CRITICALLY ILL PATIENTS; ADMINISTRATION AND DOSAGE;

D O I：

10.1179/joc.1995.7.1.45

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Considering the low therapeutic index of the aminoglycosides it is mandatory to monitor serum concentrations (SC) either to obtain therapeutic levels or to avoid toxic levels. The SC of amikacin (AMK) was evaluated in 24 inpatients in an intensive care unit of Hospital Sao Joao, mean age (+/- SD) 45.5+/-18.57 years. In 62.5% of the patients it was shown that SC (mean +/- SD, 16.87+/-1.62) was inferior to the therapeutic range. In 33.3% the values (SC 25.85+/-3.77) were within the therapeutic window (> 20 mu g/ml; < 35 mu g/ml). Only 1 patient attained toxic levels (> 35 mu g/ml). In 4 of the patients with initial SC< 20 mu g/ml, dosage was adjusted and thereafter therapeutic value was obtained (SC 24.65 +/- 3.38). The relation between the administered dose and the dosage usually recommended (weight X 15 mg/day) was calculated. In the majority of our patients (the so-called ''critically ill patients'') the recommended dosages of AMK need to be increased in order to get the desired SC. In the population of this study a dosage of about 120% relative to the initial recommended dosage was necessary.

引用

页码：45 / 49

页数：5

共 22 条

[1]

Banks B.C., Monitoring aminoglycosides, J Antimicrob Chemother, 26, pp. 145-148, (1990)

[2]

Reeves D.S., Therapeutic drug monitoring of aminoglycoside antibiotics, Infection, 8, pp. S313-S320, (1980)

[3]

Edason R.S., Terrel C.L., The aminoglycosides, Mayo Clin Proc, 66, pp. 1158-1164, (1991)

[4]

Phillips I., Good antimicrobial prescribing - aminoglycosides, Lancet, 2, pp. 311-315, (1982)

[5]

Sarubbi F.A., Hull J.H., Amikacin serum concentrations: Prediction of levels and dosage guidelines, Ann Intern Med, 89, pp. 612-618, (1978)

[6]

Lancet, 2, pp. 670-671, (1986)

[7]

Cronin R.E., Aminoglycosides nephrotoxicity: Pathogene is and prevention, Clin Nephrol, 11, pp. 251-256, (1979)

[8]

Moore R.D., Lietman P.S., Smith C.R., Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration, J Infect Dis, 1, pp. 93-99, (1987)

[9]

Moore R.D., Smith C.R., Lietman P.S., Association of aminoglycoside plasma level with therapeutic outcome in gram-negative bacteremia, Am J Med, 77, pp. 657-662, (1984)

[10]

Moore R.D., Smith C.R., Lietman P.S., The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia, J Infect Dis, 149, pp. 443-488, (1984)

← 1 2 3 →